Adar Poonawalla, CEO, Serum Institute of India (SII) said as per the arrangement with AstraZeneca, SII will be making one billion doses of Covishield vaccine over the next one year for India and other low-and-middle-income countries (GAVI countries).
Neuberg, India's fourth largestpathology player, had earlier received approvals for COVID testing in Ahmedabad, Bengaluru, Chennai and Pune, it said in a press release.
The World Health Organisation (WHO) has said the first use of COVID-19 vaccinations cannot be expected until early 2021. The statement comes at a time when over 150 COVID-19 vaccines are at different stages of development, with a few advancing to the late-stage clinical trial.
Microsoft co-founder Bill Gates has said that people could need multiple doses of a potential coronavirus vaccine to immunize oneself.
Oxford-Astrazeneca joint collaboration vaccine is now a frontrunner in the race to find a shield immunity against COVID-19, the disease which has already infected over 15 million people worldwide. In a latest development, the vaccine is now being manufactured in the Pune based Serum Institute of India.
Chennai's SRM Medical Hospital has begun the first phase of human clinical trials of the indigenous COVID-19 vaccine.
Oxford University has reported satisfactory progress from the vaccines test results and is conducting bigger field tests in the UK. In India, it has chosen SII as manufacturing partner, which has to conduct field trials before getting the final nod to ensure they are safe and effective for Indians.
Oxford coronavirus vaccine, whose results of Phase I, II trials have appeared safe, will be called 'Covishield' in India, says Adar Poonawalla, CEO, Serum Institute of India, a Pune based manufacturing partner of AstraZeneca that will be producing 1 billion doses of the Oxford's corona vaccine.
Pfizer, which has struck a nearly $2 billion deal with the US government to deliver 100 million doses of a COVID-19 vaccine developed in collaboration with its German partner BioNTech, is hoping to seek regulatory approval for a vaccine "as early as October" this year and have a vaccine on the market by year end.
The US government has agreed to pay $1.95 billion for 100 million doses of a potential Covid-19 vaccine jointly developed by Pfizer and BioNTech, the two companies said on Wednesday.
Scientists have genetically modified a "mild virus" which generates antibodies in humans just like the novel coronavirus, but without causing severe disease, an advance which they say will enable more labs across the world to safely test drugs and vaccine candidates against COVID-19.
Amid speculations of researchers across the globe making great inroads into developing coronavirus vaccines, Serum Institute of India CEO, Adar Poonawalla has disclosed information on how much the vaccine could cost in India.
Serum Institute of India will be starting trials of the COVID-19 vaccine candidate developed by Oxford University and AstraZeneca by the end of August on up to 5,000 Indian volunteers after getting the necessary nods.
The COVID-19 vaccine developed by scientists at the Oxford University produces strong immune responses in both parts of the immune system, showed results of the Phase I/II trial published in The Lancet medical journal.
Team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University’s Jenner Institute working on the discovery of a safe, effective and accessible vaccine against coronavirus.
Scientists, including one of Indian-origin, have developed a COVID-19 vaccine candidate, which they say generates antibodies that "potently neutralise" the novel coronavirus in mice and primates with a single immunisation.
After coronavirus vaccine AstraZeneca developed by the University of Oxford prompted a strong immune response in over a thousand people who had got the shot, a leading researcher working on the vaccine, Andrew Pollard said the first milestone with the research has been achieved but "it still needs to be seen if the vaccine works."
Glenmark Pharmaceuticals on Tuesday said its generic version of antiviral drug Favipiravir, FabiFlu, is more economical and effective than other drugs available in the market approved for emergency use for treatment of COVID-19.
Serum Institute of India, the largest vaccine manufacturer in the world, is a partner in the Oxford vaccine project and has been chosen by Oxford and AstraZeneca to manufacture the vaccine once it gets ready.
Team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University’s Jenner Institute working on the discovery of a safe, effective and accessible vaccine against coronavirus have come out with the trial results that the world was waiting for. The results of Phase I/II trial published in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses.
Top News
Latest News
